Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
Authors
Keywords
-
Journal
JAMA Internal Medicine
Volume 182, Issue 5, Pages 513
Publisher
American Medical Association (AMA)
Online
2022-03-28
DOI
10.1001/jamainternmed.2022.0338
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
- (2021) Young Jin Tak et al. Current Obesity Reports
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 receptor agonists: fighting obesity with an eye to cardiovascular risk
- (2021) Giovanna Liuzzo et al. EUROPEAN HEART JOURNAL
- Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
- (2021) Rita R. Kalyani NEW ENGLAND JOURNAL OF MEDICINE
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
- (2021) Julie R. Lundgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses
- (2021) Ting Cai et al. BMJ-British Medical Journal
- Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
- (2021) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
- (2021) Juris J. Meier Frontiers in Endocrinology
- Cholelithiasis in patientes treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials
- (2020) Besmir Nreu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
- (2020) Nikolaus Marx et al. Lancet Diabetes & Endocrinology
- The number needed to treat in pairwise and network meta-analysis and its graphical representation
- (2019) Areti Angeliki Veroniki et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
- (2019) Rasmus M. Christensen et al. DRUG SAFETY
- Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
- (2019) Michael A. Nauck et al. DIABETES CARE
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk
- (2019) Niko Marx et al. EUROPEAN HEART JOURNAL
- Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics
- (2018) Jennifer B. Green et al. AMERICAN HEART JOURNAL
- New avenues in the regulation of gallbladder motility - implications for the use of glucagon-like peptide-derived drugs
- (2018) Ida M Gether et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Unknown
- (2018) DIABETES OBESITY & METABOLISM
- Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs
- (2018) Jens F. Rehfeld et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Unknown
- (2017) JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus
- (2016) Jean-Luc Faillie et al. JAMA Internal Medicine
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2013) Alessandro Liberati ANNALS OF INTERNAL MEDICINE
- Abstracts of the 49th Annual Meeting of the EASD
- (2013) DIABETOLOGIA
- Abstracts of the 48th EASD Annual Meeting of the European Association for the Study of Diabetes
- (2012) DIABETOLOGIA
- Abstracts of the 47th Annual Meeting of the EASD, Lisbon 2011
- (2011) DIABETOLOGIA
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now